UNITED THERAPEUTICS CORP

Discover how United Therapeutics’ 10(b)(5)(1) plan fuels steady cash flow, stable insider ownership, and minimal market impact—insights for investors.

CEO Martine Rothblatt’s latest 10‑b‑5‑1 trade shows routine insider liquidity moves—buying 9,500 shares while selling options, a subtle signal for investors to watch future earnings impact.

United Therapeutics insider trading shows CEO Martine Rothblatt’s disciplined option sales and shares purchases, underscoring confidence in UTX’s biotech pipeline and stable valuation.

United Therapeutics insider trading shows a routine 10(b5‑1) plan by CEO Rothblatt, signaling steady confidence and no sudden price shift—solid for investors.

Insider trading at United Therapeutics shows disciplined 10b5‑1 plan buying and selling—CEO Rothblatt’s moves confirm confidence in the company’s $560‑$570 price range while underscoring strong insider ownership and future pipeline prospects.

United Therapeutics CFO’s disciplined 10(b)(5)(1) trades reveal insider confidence—steady buys and sells around $570 support long‑term value.

Discover how United Therapeutics CEO Martine Rothblatt’s structured 10(b)(5)(1) trading plan reflects confidence in the company’s growth, guiding investors through Q1 earnings and future pipeline prospects.

Executive buying & selling at UTHR shows confidence in growth; a disciplined 10b‑5‑1 plan signals long‑term upside for United Therapeutics investors.

United Therapeutics insider trades show CEO confidence amid buzz; balanced option exercise and sales hint at solid fundamentals and future biotech growth.

Insider activity shows United Therapeutics’ executives are following routine 10(b)(5) plan trades, confirming confidence in the company’s pipeline and valuation.